Frontiers in Oncology (Oct 2021)
Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence
- Jinliang Yu,
- Zhiyuan Sheng,
- Zhiyuan Sheng,
- Shuang Wu,
- Shuang Wu,
- Yushuai Gao,
- Yushuai Gao,
- Zhaoyue Yan,
- Zhaoyue Yan,
- Chaojie Bu,
- Chaojie Bu,
- Jianjun Gu,
- Jianjun Gu,
- Yage Bu,
- Yage Bu,
- Kaiyuan Deng,
- Kaiyuan Deng,
- Sensen Xu,
- Sensen Xu,
- Zhongcan Chen,
- Zhongcan Chen,
- Qianqian Zhang,
- Ajmal Zemmar,
- Juha Hernesniemi,
- Juha Hernesniemi,
- Meiyun Wang,
- Meiyun Wang,
- Gang Liu,
- Tianxiao Li,
- Tianxiao Li,
- Xingyao Bu,
- Xingyao Bu
Affiliations
- Jinliang Yu
- Department of Neurosurgery, Children’s Hospital Affiliated to Zhengzhou University, Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou, China
- Zhiyuan Sheng
- Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
- Zhiyuan Sheng
- Juha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Shuang Wu
- Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
- Shuang Wu
- Juha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Yushuai Gao
- Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
- Yushuai Gao
- Juha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Zhaoyue Yan
- Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
- Zhaoyue Yan
- Juha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Chaojie Bu
- Juha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Chaojie Bu
- Juha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Jianjun Gu
- Juha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Jianjun Gu
- Juha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Yage Bu
- Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
- Yage Bu
- Juha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Kaiyuan Deng
- Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
- Kaiyuan Deng
- Juha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Sensen Xu
- Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
- Sensen Xu
- Juha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Zhongcan Chen
- Juha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Zhongcan Chen
- Juha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Qianqian Zhang
- Juha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Ajmal Zemmar
- Juha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Juha Hernesniemi
- Juha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Juha Hernesniemi
- Juha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Meiyun Wang
- Department of Medical Imaging, Henan Provincial People’s Hospital, The People’s Hospital of Zhengzhou University, Zhengzhou, China
- Meiyun Wang
- Henan Provincial Key Laboratory for Imaging Diagnosis and Research of Neurological Diseases, Henan Provincial People’s Hospital, The People’s Hospital of Zhengzhou University, Zhengzhou, China
- Gang Liu
- Department of Center for Clinical Single Cell Biomedicine, Clinical Research Center, Department of Oncology, Henan Provincial People’s Hospital, The People’s Hospital of Zhengzhou University, Zhengzhou, China
- Tianxiao Li
- Juha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Tianxiao Li
- Juha International Center for Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- Xingyao Bu
- Department of Neurosurgery, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
- Xingyao Bu
- Juha International Central Laboratory of Neurosurgery, Henan Provincial People’s Hospital, Zhengzhou, China
- DOI
- https://doi.org/10.3389/fonc.2021.742037
- Journal volume & issue
-
Vol. 11
Abstract
The recurrence of glioma is a difficult problem in clinical treatment. The molecular markers of primary tumors after resection cannot fully represent the characteristics of recurrent tumors. Here, abundant tumor DNA was detected in tumor in situ fluid (TISF). We report that TISF-derived tumor DNA (TISF-DNA) can detect genomic changes in recurrent tumors and facilitate recurrence risk analysis, providing valuable information for diagnosis and prognosis. The tumor DNA in TISF is more representative and sensitive than that in cerebrospinal fluid. It reveals the mutational landscape of minimal residual disease after glioma surgery and the risk of early recurrence, contributing to the clinical management and clinical research of glioma patients.
Keywords
- precision medicine
- tumor in-situ fluid
- circulating tumor DNA
- spatiotemporal heterogeneity
- glioma progression
